Jyong Biotech Ltd (MENS)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Jyong Biotech Ltd, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Based on dividend-adjusted daily data since Jun 17, 2025, MENS's average daily return is +0.23%, while the average monthly return is +10.76%. At this rate, your investment would double in approximately 0.6 years.

Historically, 40% of months were positive and 60% were negative. The best month was Aug 2025 with a return of +187.6%, while the worst month was Dec 2025 at -85.5%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 4 months.

On a daily basis, MENS closed higher 49% of trading days. The best single day was Dec 30, 2025 with a return of +51.8%, while the worst single day was Dec 17, 2025 at -81.0%.

Jyong Biotech Ltd has an annualized alpha of 30.48%, beta of 2.66, and R² of 0.03 versus S&P 500 Index. Calculated based on daily prices since June 18, 2025.

• This stock participated in 458.37% of S&P 500 Index downside but only 432.27% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.03 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

The table below present risk-adjusted performance metrics for Jyong Biotech Ltd (MENS) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Jyong Biotech Ltd. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Jyong Biotech Ltd was 97.78%, occurring on Feb 11, 2026. The portfolio has not yet recovered.

The current Jyong Biotech Ltd drawdown is 96.72%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Jyong Biotech Ltd over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Jyong Biotech Ltd is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.